Cleveland·Miami·Basel·Tel AvivForce Multipliers  ·  Elevate Humanity
Home / Insights / Growth Equity
Insights

Growth Equity

LeverVenture is an operator-led, mid-market growth equity firm in life sciences and healthcare, the bridge between venture capital and private equity. These pieces cover that passage: deal structures, market conditions, finance and the operating work that carries a company from proof to scale.

Field notes, diligence method, operating and capital Written by the partner or operator who did the work
§ 01  /  02
The archive

Filed under Growth Equity, newest first.

The most recent piece leads and every other piece in this category follows it, each with the line that says what it covers. The other categories are one link away.

Most recent
Growth Equity17 Sep 2026  ·  15 min read

Growth Equity in Life Sciences: 2026 Market Study

Growth equity is absorbing a growing share of life sciences and healthcare capital. This market study breaks down the data, the five sectors in play, and where the financing gap actually sits.

José VasquézBy José Vasquéz
Read the piece
Browse by category
By author

Growth Equity

The full index

Everything else filed under Growth Equity, newest first.

Growth Equity16 Sep 2026  ·  11 min

Operational Due Diligence: The GP Checklist Nobody Publishes

Operational due diligence tests whether a manager's documents describe what the firm actually does. The checklist and reference-call script a general partner should expect to answer.

Read this piece
Growth Equity08 Sep 2026  ·  7 min

Private Equity Meets the Mid-Market: Borrowing PE's Discipline Without the Buyout

Private equity and venture are converging in the mid-market. What growth companies should borrow from PE — operational value creation, cash discipline, governance — and what they should refuse: control and leverage.

Read this piece
Growth Equity02 Sep 2026  ·  11 min

The Operating Record: What It Supports and What It Does Not

An operating record shows what partners did inside companies. Read by evidence class, it supports claims about capability and conduct, not returns or causation.

Read this piece
Growth Equity01 Sep 2026  ·  9 min

Family Office Guide to Emerging Growth Equity Managers

A practical framework for family offices evaluating first-time and early-fund growth equity managers: what to check, what to ignore, and the red flags that matter most.

Read this piece
Growth Equity25 Aug 2026  ·  18 min

The Term Sheet Guide for Life Sciences and Healthcare Founders

Term sheets carry more weight than the valuation headline. This guide walks life sciences and healthcare founders through the economic terms, control terms, and sector-specific issues to watch.

Read this piece
Growth Equity21 Aug 2026  ·  7 min

The State of Venture Capital: How the Power Law Broke the Middle — and What Comes Next

Venture capital is a power-law business, and the end of cheap money exposed a missing rung in the ladder — the Series B/C graduation problem. Why DPI is back, and where the orphaned middle finds capital.

Read this piece
Growth Equity13 Aug 2026  ·  11 min

What a First-Time Fund's Back Office Actually Looks Like

A first-time fund rents most of its back office. The general partner keeps oversight, valuation, the compliance calendar and cash authority, and failures start at the handoffs.

Read this piece
Growth Equity11 Aug 2026  ·  8 min

Operator-Led vs. Financial-Sponsor Growth Equity: What an Operating Partner Changes for LPs

Two models of growth capital get lumped together as "private equity." This piece separates operator-led from financial-sponsor growth equity and what the difference means for LPs.

Read this piece
Growth Equity04 Aug 2026  ·  7 min

The Finance of Scaling: A Growth-Stage Operator's Guide to the Metrics That Move Enterprise Value

The financial rules change between the seed round and the buyout. A growth equity guide to unit economics, the Rule of 40, capital structure, cash strategy, and the metrics that actually move enterprise value.

Read this piece
Growth Equity14 Jul 2026  ·  10 min

The J-Curve Is Different in Life Sciences, and Allocators Should Price It

In life sciences, regulatory clocks set the J-curve. Drug approval takes 10.5 years on average from Phase I, so the trough runs longer and reported value moves in steps.

Read this piece
Growth Equity23 Jun 2026  ·  12 min

DPI Is the Only Number an Allocator Should Trust Right Now

Median DPI for 2018 to 2020 private equity vintages runs from 0.56x down to 0.16x while TVPI and IRR stay high. Most reported value is still a mark; DPI is the figure settled in cash.

Read this piece
Growth Equity16 Jun 2026  ·  5 min

Dual-Use Deep Tech: The Defense-Adjacent Growth-Equity Playbook for Founders

Defense-adjacent deep tech is reshaping how founders in life sciences, clean tech, and AI should structure their commercialization and funding strategy. Here's the operator-level view.

Read this piece
Growth Equity09 Jun 2026  ·  11 min

Carried Interest: European and American Waterfalls, Side by Side

On one hypothetical $100 million fund, a deal-by-deal waterfall pays $15 million of carry by year three and a whole-of-fund waterfall pays $10 million. A clawback closes the gap.

Read this piece
Growth Equity05 Jun 2026  ·  10 min

Emerging Growth Equity Managers: The Founder's Complete Evaluation Guide for 2026

How founders in life sciences, deep tech, and cleantech should evaluate emerging growth equity managers — track record, fund economics, GP skin-in-the-game, and red flags.

Read this piece
Growth Equity29 May 2026  ·  15 min

Best Growth Equity Firms for Life Sciences in 2026: A Founder's Field Guide

Who actually funds life sciences growth rounds, what each pool of capital is built for, where the mid-market gap sits, and the questions that vet a partner.

Read this piece
Growth Equity19 May 2026  ·  11 min

The Operating Partner's First Hundred Days, With Owners and Dates

A minority investor's operating partner runs no workstreams. The first hundred days rest on written rights, a compliance baseline and a plan with owner roles and dates.

Read this piece
Growth Equity05 May 2026  ·  11 min

Key Person, GP Commitment and Source of Funds in a Two-Partner Firm

In a two-partner firm, the key person provision, the GP commitment and its source of funds work as one alignment mechanism. ILPA's Model LPA and Principles 3.0 set the market form.

Read this piece
Growth Equity07 Apr 2026  ·  12 min

Continuation Funds, Read From the GP's Side

A continuation fund puts the sponsor on both sides of a sale. With the SEC fairness-opinion rule vacated, the fiduciary duty, the LPA and ILPA's 2023 guidance govern the choice.

Read this piece
Growth Equity24 Mar 2026  ·  10 min

SPV, Fund or Co-Invest: Choosing the Vehicle

An SPV, a pooled fund and a direct co-investment can hold the same shares, but each answers the Investment Company Act, Regulation D and adviser questions differently.

Read this piece
Growth Equity10 Mar 2026  ·  10 min

Value Creation in a Company You Do Not Control

A minority growth investor works through four levers: a board seat, information rights, protective provisions and operating engagement. Each has a documented use and a documented limit.

Read this piece
Growth Equity20 Sep 2025  ·  6 min

VC Market Reset: Implications for Growth Equity Investors

A venture repricing shows up in preference stacks and flat rounds before it shows up in a press release. Here is how a reset moves through a cap table.

Read this piece
Growth Equity26 Aug 2025  ·  8 min

Secondary Markets in Growth Equity: 2025 Liquidity Revolution

Secondary markets hit all-time highs in the first half of 2025, with transaction volume above $103 billion. Growth equity investors gain new routes to liquidity.

Read this piece
Growth Equity21 Aug 2025  ·  5 min

SaaS Business Models: Evolution Beyond the Rule of 40

The Rule of 40 flattens very different SaaS businesses into one score. Retention composition, cohort payback, margin trend and burn multiple tell them apart.

Read this piece
§ 02  /  02
Research

The State of Growth Equity, 2026 edition.

The first edition of our read on the passage between venture capital and private equity: who is funding it, what it costs, and where the companies that stall in it actually stall.

01

Executive summary

Free, no form. The findings, the method and every chart that carries one — complete, not a teaser, and the same text that opens the full report.

02

The full report

Sixty-four pages, this first edition, released to a named reader. One form, one reply, and no list you did not ask to be on.

Go to the research
Contact

Have a question about something here, or want to discuss it? We would be glad to hear from you.

The 2026 study